SYBX Projected Dividend Yield
Synlogic Inc ( NASDAQ : SYBX )Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. Co. is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). Co.'s early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. 20 YEAR PERFORMANCE RESULTS |
SYBX Dividend History Detail SYBX Dividend News SYBX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |